Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chuanhuning is a semi-synthetic derivative of andrographolide, specifically potassium dehydroandrograpolide succinate, which is extracted from the traditional Chinese medicinal herb *Andrographis paniculata*. It is widely used in China as an injectable anti-inflammatory and antiviral medication. The drug's mechanism of action involves the inhibition of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), and high-sensitivity C-reactive protein (hs-CRP), which are often elevated in respiratory infections. Chuanhuning is primarily indicated for the treatment of viral upper respiratory tract infections, viral pneumonia, and acute exacerbations of chronic obstructive pulmonary disease (AECOPD). It is known to possess antipyretic properties and can enhance the phagocytic activity of white blood cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chuanhuning.